Erratum

CB₁ Agonist ACEA Protects Neurons and Reduces the Cognitive Impairment of AßPP/PS1 Mice

Ester Aso, Ernest Palomer, Salvador Juvés, Rafael Maldonado, Francisco J. Muñoz and Isidro Ferrer

[Journal of Alzheimer's Disease **30**(1), 2012, 439-459, DOI 10.3233/JAD-2012-111862] http://iospress.metapress.com/content/a2w455754v142887/

The A β oligomer concentration employed on the P-Ser9-glycogen synthase kinase-3 β (GSK3 β) immunolabelling and western blotting assays was 0.1 μ M instead of 1 μ M A β . In consequence, the following corrections should be made:

(1) Page 443, Section "P-Ser9-glycogen synthase kinase-3 β (GSK3 β) immunolabelling assay", 5th line, the correct text should read "Cells were incubated for 30 min with 1 μ M ACEA and PBS (control) or 0.1 μ M A β oligomers".

- (2) Page 443, Section "P-Ser9-GSK3 β quantification. Cortical neurons", 6th line, the correct text should read "Then, ACEA 1 μ M and PBS (control) or 0.1 μ M A β oligomers were added to wells".
- (3) Page 455, the section (A) of Figure 9 legend should read "Double immunofluorescent staining of phospho-GSK3 β (green) and tubulin (red) in cortical primary culture challenged with 0.1 μ M A β 42 oligomers and treated with 1 μ M ACEA"
- (4) The Figure 9 should be modified. The correct figure is shown below:

